Evaluation of the association between IL28B polymorphisms and sustained virologic respond in patient with chronic hepatitis c who were followed at Akdeniz University infectious disease department

Although the standart treatment of chronic hepatitis C is pegIFN+RBV, new treatment regimens with or without IFN was approved in recent years. For all treatment regimens sustained virologic response is defined as an undetectable HCV RNA level (<50 IU/ml) 24 weeks after the end of therapy. In recent years studies on genetic factors that affect SVR has been started. The most researched in these factors that identified in the IL28B gene on chromosome 19 is single nucleotide polymorphisms. In studies patients who have rs12979860 and rs8099917 major genotype, detected the probability of receiving SVR was high. In this study we aimed to demonstrate the association between IL28B gene polimorphisms and sustained virologic response in patient with chronic hepatitis C who were followed at Akdeniz University Infectious Disease Department. Fourty HCV genotype-1 infected adult patients aged 18-65 who have taken pegIFN+RBV treatment and have followed at least 6 months after the end of therapy were selected in this study. For genotype analysis of patients blood samples were collected after informed consent. The relationship between genotype analysis, pretreatment biochemical and demographic characteristics, monitored features during treatment and SVR were retrospectively evaluated. The most common rs12979860 genotype in patients is CT with a ratio of 60%, the TT genotype of rs8099917 with a ratio of 57.5%, respectively. In univariate analysis EVR was significantly higher in patients receiving SVR than non SVR. SVR was significantly higher in 12979860 CC genotype compared to non CC. EVR and SVR was significantly higher in rs8099917 TT genotype compared to non TT. Multivariate logistic regression analysis showed a significant association with SVR was observed only with rs8099917 TT genotype and ALT. In our study we determine the distribution of IL28B genotype of Turkish Society and we showed the datas are compatible with the White race. Before the treatment to predict SVR we think IL28B genotypes may be taken into consideration. However, we must evaluate each patient together with other features that affect SVR and treatment decision for patients must be decided in private